 |
 |

Antilymphoid Sera in Renal Allotransplantation
Roy G. Shorter, MD;
George A. Hallenbeck, MD;
Carlos Nava, MD;
Hugh O. O'Kane, MB, BSc, FRCS;
James H. DeWeerd, MD;
William J. Johnson, MD
AMA Arch Surg. 1968;97(2):323-329.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
BECAUSE of observations by others1-7 on the effects of heterologous antilymphoid sera (ALS) and experiences in the laboratory with the use of antithymus serum as the single immunosuppressive agent in achieving prolongation of survival of allografts of skin (P. Sutthiwan et al, unpublished data) and xenografts of tumor in mice8 we decided to test the immunosuppressive effects of such sera in the allografting of livers and kidneys in dogs, and subsequently to proceed with a trial of the material in the clinical renal transplant program at the Mayo Clinic. The experiments involving hepatic allografting in dogs have been reported elsewhere,9 and the purposes of this presentation are to describe the results obtained in canine renal allografting and to review the findings of a preliminary clinical trial in human beings. In animals, the sera were used as the sole means of immunosuppression; in the clinical situation, however, testing
. . . [Full Text PDF of this Article]
Author Affiliations
Rochester, Minn
From the sections of organ and tissue transplantation (Drs. Shorter and Hallenbeck), urology (Dr. Deweerd), and nephrology (Dr. Johnson), Mayo Clinic and Foundation, and sections of surgery (Dr. Nava), and surgical research (Dr. O'Kane), Mayo Graduate School of Medicine (University of Minnesota), Rochester.
Footnotes
Submitted for publication March 22, 1968.
Read before the 25th annual meeting of the Central Surgical Association, Cleveland, Feb 23, 1968.
Reprint requests to Mayo Clinic, 200 First St SW, Rochester, Minn 55901.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|